摘要
目的观察罗格列酮治疗2型糖尿病患者在改善胰岛素抵抗方面的疗效。方法对10例血糖控制满意的2型糖尿病患者，采用评价胰岛素敏感性金指标-正常血糖高胰岛素钳夹法，评价应用罗格列酮4mg／日治疗12周后改善胰岛素敏感性的疗效。结果反映血糖控制情况的空腹血糖[（6．82±0．91）% vs.（6．54±0．74）mmol／L]和糖化血红蛋白[（6．52±0.83）％vs ．（6．44±0．82）％]治疗前后差异均无统计学意义；而反映胰岛素敏感性的空腹胰岛素[（16．44±0．97）绑．（12．45±1．21）mU／L]、稳态模型指数（7．44±1．76／35．4．13±1．15）、葡萄糖代谢率[（1．56±0．35）vs．（4．76±1．61）mg·kg^-1·min^-1]及胰岛素敏感指数[葡萄糖代谢率与胰岛素之比，（0．0173±0．0053）135．（0．0461±0．0113）mg·kg^-1·min^-1·（mU／L）。]治疗后均较治疗前显著改善（P〈0．05，P〈0．001）。结论正常血糖高胰岛素钳夹法所测胰岛素敏感指标能明确量化并能更好地反映具有胰岛素抵抗2型糖尿病患者经过罗格列酮治疗的效果。
Objective To determine the effect of the thiazohdinediones rosiglitazone on insulin resistance in patients with type 2 diabetes. Methods In 10 subjects with type 2 diabetes whose glycemic levels were well controlled, rosiglitazone 4 mg/d was added for 12 weeks. At basehne and at the end of the treatment period, hyperinsulinemic euglycemic clamp was applied to evaluate the effect of thiazolidinediones rosiglitazone on insulin resistance. Blood tests were performed to determine glucose, insulin, hemoglobin Alc, and routine laboratory parameters. Resuits The fasting plasma glucose [ （6. 82±0. 91 ） vs. （6. 54 ±0. 74） mmol/L] and hemoglobin Alc [ （6. 52 ± 0. 83）% vs. （6. 44 ± 0. 82）% ] after rosiglitazone treatment did not significantly change. The fasting insulin [ （ 16. 44 ±0. 97） vs. （ 12. 45 ± 1.21 ） mU/L] and the homeostasis model assessment index significantly decreased （7.44±1.76 vs. 4. 13±1.15）, while the hyperinsulinemic euglycemic clamp significantly increased [ glucose metabolic rate/insulin （0.0173 ±0.0053） vs. （0.0461±0. 0113） mg·kg^-1·min^-1 （mU/L） -1 glucose metabolic rate： （1.56±0.35） vs. （4.76±1.61） mg·kg^-1·min^-1, （P〈0.05, P〈0.001）. Conclusion When trea- ting type 2 diabetic patients with insulin resistance, rosiglitazone can remarkably increase insulin sensitivity, which can be effectively estimated by hyperinsulinemic englycemic clamp quantitively.
出处
《中华临床营养杂志》
CAS
2009年第3期133-135,共3页
Chinese Journal of Clinical Nutrition
基金
北京市科委重点科研项目（H030930010230）
